Avenue Therapeutics (ATXI) Competitors $1.36 -0.04 (-2.86%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.32 -0.04 (-2.94%) As of 02/21/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends ATXI vs. TSBX, BCLI, JAGX, BGXX, CHRO, RLMD, NLSP, AYTU, APM, and AIMShould you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Turnstone Biologics (TSBX), Brainstorm Cell Therapeutics (BCLI), Jaguar Health (JAGX), Bright Green (BGXX), Chromocell Therapeutics (CHRO), Relmada Therapeutics (RLMD), NLS Pharmaceutics (NLSP), Aytu BioPharma (AYTU), Aptorum Group (APM), and AIM ImmunoTech (AIM). These companies are all part of the "pharmaceutical products" industry. Avenue Therapeutics vs. Turnstone Biologics Brainstorm Cell Therapeutics Jaguar Health Bright Green Chromocell Therapeutics Relmada Therapeutics NLS Pharmaceutics Aytu BioPharma Aptorum Group AIM ImmunoTech Avenue Therapeutics (NASDAQ:ATXI) and Turnstone Biologics (NASDAQ:TSBX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, community ranking, earnings, risk, valuation and profitability. Do institutionals & insiders have more ownership in ATXI or TSBX? 17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 52.5% of Turnstone Biologics shares are owned by institutional investors. 1.8% of Avenue Therapeutics shares are owned by company insiders. Comparatively, 32.1% of Turnstone Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, ATXI or TSBX? Avenue Therapeutics has a beta of -0.28, suggesting that its share price is 128% less volatile than the S&P 500. Comparatively, Turnstone Biologics has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500. Does the media prefer ATXI or TSBX? In the previous week, Avenue Therapeutics' average media sentiment score of 0.00 equaled Turnstone Biologics'average media sentiment score. Company Overall Sentiment Avenue Therapeutics Neutral Turnstone Biologics Neutral Does the MarketBeat Community prefer ATXI or TSBX? Avenue Therapeutics received 143 more outperform votes than Turnstone Biologics when rated by MarketBeat users. Likewise, 60.25% of users gave Avenue Therapeutics an outperform vote while only 44.44% of users gave Turnstone Biologics an outperform vote. CompanyUnderperformOutperformAvenue TherapeuticsOutperform Votes14760.25% Underperform Votes9739.75% Turnstone BiologicsOutperform Votes444.44% Underperform Votes555.56% Do analysts recommend ATXI or TSBX? Turnstone Biologics has a consensus target price of $0.45, suggesting a potential upside of 15.80%. Given Turnstone Biologics' stronger consensus rating and higher probable upside, analysts clearly believe Turnstone Biologics is more favorable than Avenue Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Turnstone Biologics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Is ATXI or TSBX more profitable? Turnstone Biologics' return on equity of -105.99% beat Avenue Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avenue TherapeuticsN/A -471.57% -296.50% Turnstone Biologics N/A -105.99%-87.27% Which has better earnings and valuation, ATXI or TSBX? Avenue Therapeutics has higher earnings, but lower revenue than Turnstone Biologics. Turnstone Biologics is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvenue TherapeuticsN/AN/A-$10.38M$18.350.07Turnstone Biologics$19.31M0.47-$55.20M-$3.24-0.12 SummaryTurnstone Biologics beats Avenue Therapeutics on 8 of the 13 factors compared between the two stocks. Get Avenue Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXI vs. The Competition Export to ExcelMetricAvenue TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.79M$7.04B$5.77B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio0.076.1326.4618.82Price / SalesN/A313.76455.0280.40Price / CashN/A67.8344.0437.47Price / Book0.716.747.634.64Net Income-$10.38M$138.11M$3.18B$245.69M7 Day PerformanceN/A-2.43%-1.91%-2.66%1 Month Performance-21.39%-1.91%-0.19%-2.15%1 Year Performance-87.25%-5.03%16.70%12.90% Avenue Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXIAvenue Therapeutics1.2891 of 5 stars$1.36-2.9%N/A-87.9%$2.88MN/A0.074TSBXTurnstone Biologics1.5263 of 5 stars$0.43-3.1%$0.45+4.2%-84.1%$9.99M$19.31M-0.1382Gap UpBCLIBrainstorm Cell Therapeutics4.0694 of 5 stars$1.72+0.4%$30.00+1,644.2%-62.9%$9.80MN/A-0.3640Analyst ForecastNews CoverageJAGXJaguar Health0.3116 of 5 stars$0.82-3.4%N/A-78.8%$9.69M$10.48M0.0050Gap UpBGXXBright GreenN/A$0.05+25.0%N/A-79.5%$9.56MN/A-0.832Gap UpCHROChromocell TherapeuticsN/A$1.57+22.7%N/A-64.9%$9.47MN/A0.004RLMDRelmada Therapeutics4.3231 of 5 stars$0.31-0.2%$4.25+1,278.1%-94.8%$9.30MN/A-0.1110Gap DownNLSPNLS PharmaceuticsN/A$2.57+37.4%N/A+364.1%$9.25MN/A0.006Gap UpHigh Trading VolumeAYTUAytu BioPharma1.027 of 5 stars$1.50-3.2%N/A-55.0%$9.22M$79.76M-1.22160High Trading VolumeAPMAptorum Group0.4974 of 5 stars$1.75+43.4%N/A-38.1%$9.07M$430,000.000.0030Gap UpAIMAIM ImmunoTech1.7429 of 5 stars$0.14-3.5%$2.75+1,835.3%-67.1%$9.06M$200,000.00-0.3020 Related Companies and Tools Related Companies Turnstone Biologics Alternatives Brainstorm Cell Therapeutics Alternatives Jaguar Health Alternatives Bright Green Alternatives Chromocell Therapeutics Alternatives Relmada Therapeutics Alternatives NLS Pharmaceutics Alternatives Aytu BioPharma Alternatives Aptorum Group Alternatives AIM ImmunoTech Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATXI) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCritical ‘Buy Now’ Alert on My Favorite Stock!My absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avenue Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATXI Stock Alerts